ArticleScientific reports2025
Transcriptomic analysis reveals the potential role of TOE1 in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TOE1 is a β-catenin interacting protein regulating the proliferation of hematopoietic cells through PAK2 modulation.Stem cell reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study integrates bioinformatics analysis and in vitro experiments to elucidate the role of Target of EGR1 (TOE1) in hepatocellular carcinoma (HCC) progression. TOE1, a deadenylase belonging to the DEDD exonuclease superfamily, is primarily localized in the Cajal bodies of the nucleus. While the biological functions of TOE1 have been partially characterized, its role in cancer remains unclear. We analyzed TOE1 expression, its correlation with clinicalpathological features, prognosis, and immune infiltration in HCC using databases and platforms such as The Cancer Genome Atlas (TCGA), COSMIC, cBioPortal, and TIMER. Additionally, we validated TOE1 expression levels in clinical samples. Through the knockdown of TOE1 in HCC cell lines and subsequent RNA-seq analysis, we explored its functional role and potential molecular mechanisms in HCC malignant progression. The research focused on uncovering the role of TOE1 in HCC development and its underlying mechanisms. Comprehensive bioinformatics interrogation revealed that TOE1 was significantly upregulated in HCC and was correlated with poor patient prognosis. It may influence tumor development by modulating the stemness of tumor cells and immune cell infiltration, thereby reshaping the tumor microenvironment. Furthermore, in vitro experiments suggested that TOE1 promotes HCC proliferation and metastatic potential via modulating the Hippo signaling pathway. This research highlights the pivotal role of TOE1 in HCC, indicating its promise as a novel target for early detection, therapeutic strategies, immunological intervention, and prognosis assessment in HCC. These findings provide fresh perspectives for precision medicine in the context of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.